Section Review: Biologicals & Immunologicals: Therapeutic potential of Schiff base-forming drugs

References

• WHITTINGTON R, FAULDS D: Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs (1993) 46:446–514.
   Google Scholar
• GOEDEGEBURNE PS, DOUVILLE LM, RICHMOND DC et al.: Adoptive immunotherapy with tumor-infiltrating lym-phocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. Chn. Oncol. (1995) 13:1939–1949.
   PubMed Web of Science ®Google Scholar
• BAUER M, REAMAN GH, HANK JA et al.: A Phase 11 trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Chil-dren's Cancer Group Study. Cancer (1995) 75:2959–2965.
   Google Scholar
• KLIMA N, PATARCA R, WALLING J et al.: Clinical and Immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 and interleukin-2 infusion. AIDS (1994) 8:1073–1081.
   PubMed Web of Science ®Google Scholar
• HEATON KM, GRIMM EA: Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol. Immunotber. (1993) 37:213–219.
   PubMed Web of Science ®Google Scholar
• HENDRZAK JA, BRUNDA MJ: Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab. Invest. (1995) 72:619–637.
   Google Scholar
• O'GARRA A, MURPHY K: Role of cytoldnes in determin-ing T-lymphocyte function. Curr. Opin. Immunol. (1994) 6:458–466.
   PubMed Web of Science ®Google Scholar
• TAHARA H, LOTZE MT: Anti-tumor effects of interleukin-12 (1L-12): applications for the immunotherapy and gene therapy of cancer. Gene 7ber. (1995) 2:96–106.
   Google Scholar
• SEDER RA, PAUL WE: Acquisition of lymphokine-pro-ducing phenotype by CD4+ T-cells. Ann. Rev. Immunol. (1994) 12:635–673.
   PubMed Web of Science ®Google Scholar
• DEL-PRETE G, MAGGI E, ROMAGNANI S: Human Thl and Th2 cells: functional properties, mer anisms of regu-lation, and role in disease. Lab. Invest. (1994) 70:299–306.
   PubMed Web of Science ®Google Scholar
• GOLDING B, ZAITSEVA M, GOLDING H: The potential of recruiting immune responses towards type 1 or type 2 T-cell help. Am. J. Trop. Med. Hyg. (1994) 50:33–40.
   PubMed Web of Science ®Google Scholar
• CLERICI M, SHEARER GM: The Th1-Th2 hypothesis of HIV Infection. new insights. Immunol. Today (1994) 15:575–581.
   PubMedGoogle Scholar
• NABEL GJ, CHANG AE, NABEL EG et al.: Immunotherapyfor cancer by direct gene transfer into tumors. Human Gene Ther. (1994) 5:57–77.
   PubMed Web of Science ®Google Scholar
• FENTON RT, SZNOL M, LUSTER DG, TAUB DD, LONGO DL: A Phase I trial of B7-transfected or parental lethally Irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated anti-gen presented by HLA-A2 or HLA-Al in patients with stage IV melanoma. NCI protocol T93-0161. llllMP pro-tocol 9401. Human Gene Tber. (1994) 5:1385–1399.
   Google Scholar
• RHODES J, CHEN H, HALL SR et al.: Therapeutic potentia-tion of the immune system by co-stimulatory Schiff base-forming drugs. Nature (1995) 377:71–75.
   PubMed Web of Science ®Google Scholar
• SNELL FE, DIMARI SJ: Schiff base intermediates in en- zyme catalysis. In: The Enzymes: Kinetics and Mechanism (Volume 2). Boyer PD (Ed.), Academic Press, London (1970):335–346.
   Google Scholar
• JOHN RA: Pyridoxal phosphate-dependent enzymes. Biochim. Biophys. Acta (1995) 1248:81–96.
   PubMed Web of Science ®Google Scholar
• FHERST A: Covalent catalysis. In: Enzyme Structure andMechanism (2nd Edition). WH Freeman, New York (1984):69–97.
   Google Scholar
• VAN DER MEER RA, DUINE JA: Covalently bound pyrrolo-quinoline quinone is the organic prosthetic group of human placental lysyl oxidase. Biochem. J. (1986) 239:789–791.
   PubMed Web of Science ®Google Scholar
• STRYER L: Excitable membranes and sensory systems.In: Biochemistry (3rd Edition). WH Freeman, New York (1988):1005–1041.
   Google Scholar
• MUKOHATA Y: Comparative studies on ion pumps ofthe bacterial rhodopsin family. Biophys. Chem. (1994) 50:191–201.
   PubMed Web of Science ®Google Scholar
• SASAKI J, BROWN LS, CHON Y-S et al.: Conversion ofbacteriorhodopsin into a chloride ion pump. Science (1995) 269:73–75.
   PubMed Web of Science ®Google Scholar
• PAUL W: The immune system: an introduction. In: Fundamental Immunology (3rd Edition). Paul W (Ed.), Raven Press, New York (1993):1–20.
   Google Scholar
• HOWARD MC, MIYAJIMA A, COFFMAN R: T-cell derivedcytokines and their receptors. In: Fundamental Immu-nology (3rd Edition). Paul W (Ed.), Raven Press, New York (1993):763–800.
   Google Scholar
• MONDINO A, JENIUNS MK: Surface proteins involved in T-cell co-stimulation. J. Leukoc. Biol. (1994) 55:805–815.
   PubMed Web of Science ®Google Scholar
• BLUESTONE JA: New perspectives of CD28-B7-mediated T-cell co-stimulation. Immunity (1995) 2:555–559.
   PubMed Web of Science ®Google Scholar
• BELL GM, IMBODEN JB: CD2 and the regulation of T-cell anergy. j Immunol. (1995) 155:2805–2807.
   PubMed Web of Science ®Google Scholar
• DUBEY C, CROFT M, SWAIN SL: Co-stimulatory require-ment of naive CD4+ T-cells. ICAM-1 or B7-1 can co-stimu-late naive CD4 T-cell activation but both are required for optimum response. J. Immunol. (1995) 155:45–57.
   Google Scholar
• RHODES J: Evidence for an intercellular covalent reac-tion essential in antigen specific T-cell activation. J. Immunol. (1989) 143:1482–1489.
   PubMed Web of Science ®Google Scholar
• GAO X-M, RHODES J: An essential role for constitutive Schiff base-forming ligands in antigen presentation to murine T-cell clones. J. Immunol. (1990) 144:2883–2890.
   PubMed Web of Science ®Google Scholar
• RHODES J: E-Rosettes provide an analogue for Schiff base formation in specific T-cell activation. J. Immunol. (1990) 145:463–469.
   PubMed Web of Science ®Google Scholar
• ZHENG B, BRE]. I S, TITE JP et al.: Galactose oxidation inthe design of immunogenic vaccines. Science (1992) 256:1560–1563.
   Google Scholar
• ROLAN PE, PARKER JE, GRAY SJ et al.: The pharmacoki-netics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formy1-3-hydroxyphenoxymethyll ben-zoic add), a potential anti-siclding agent, following oral administration to healthy subjects. Br. J. Pharmacol. (1993) 35:419–425.
   Web of Science ®Google Scholar
• CHEN H, ROGERS M, RHODES J: Enhancement of T-cellreceptor-dependent signalling at the level of the MAP kinase ERK2 by Schiff base-mediated co-stimulation. Manuscript in preparation.
   Google Scholar
• DUDLEY DT, PANG L, DECKER SJ et al.: A synthetic Inhibitor of the mitogen-activated protein kinase cas-cade. Proc. Natl. Acad. Sci. USA (1995) 92:7686–7689.
   PubMed Web of Science ®Google Scholar
• GREENLAW R, ROBINSON P, HEATON T et al.: Transfec-don of HLA-DR-expressing DAP.3 cells with a cDNA clone encoding the g,lycos-y1 phosphatidylinositol-linked form of lymphocyte function associated antigen-3: biochemical features and functional consequences. Int. Immunol. (1992) 4:673–680.
   Google Scholar
• HARGREAVES R, LOGIOU V, LECHLER R: The primaryalloresponse of human CD4+ T-cells is dependent on B7 (CD80), augmented by CD58, but relatively uninflu-enced by CD54 expression. Int. Immunol. (1995) 7:1501–1513 .
   Google Scholar
• WYSS DF, CHOI JS, MARIA JL et al.: Conformation andfunction of the N-linked glycan in the adhesion domain of human CD2. Science (1995) 269:1273–1278.
   PubMed Web of Science ®Google Scholar
• MALKOVSKY M, DORE C, HUNT R et al.: Enhancement ofspecific antitumor immunity in mice fed a diet enriched In vitamin A acetate. Proc. Natl. Acad. Sci. USA (1983) 80:6322–6326.
   PubMed Web of Science ®Google Scholar
• MALKOVSICY M, EDWARDS AJ, HUNT R et al.: T-cell medi-ated enhancement of host-versus-graft reactivity in mice fed a diet enriched with vitamin A acetate. Nature (1983) 302:338–340.
   PubMed Web of Science ®Google Scholar
• MALKOVSKY M, MEDAWAR PB, THATCHER DR et al.: Acquired immunological tolerance of foreign cells is impaired by a recombinant interleukin-2 or vitamin A acetate. Proc. Natl. Acad. Sci. USA (1985) 82:536–538.
   PubMed Web of Science ®Google Scholar
• BUCK J, DERGUINI F, LEVI E et at.: Intracellular signallingby 14-hydroxy-4,14-retro-retinoL Science (1 99 1) 254:1645-1656.
   Google Scholar
• DERGUINI F, NAKANISHI K, HAMMERLING U et al.: Intra-cellular signaling activity of synthetic (14R)-, (14S)-, and (14RS)-14-hydroxy-4,14-retro-retinoLBiochemistry(1994) 33:623–628.
   Google Scholar
• MEYDANI SN, RIBAYA-MERCADO JD, RUSSELL RM et al.:Vitamin 86 deficiency impairs interleukin-2 production and lymphocyte proliferation in elderly adults. Am. Clin. Nutr. (1991) 53:1275–1280.
   PubMed Web of Science ®Google Scholar
• RALL C, MEYDANI SN: Vitamin 86 and immune compe-tence. Nutritional Rev. 51:217–225.
   Google Scholar
• DEEG HJ: Ultraviolet irradiation in transplant biology: manipulation of inununity and immunogenicity. Trans-plantation (1988) 45:845–851.
   Google Scholar
• ULLRICH SE: Modulation of immunity by ultraviolet radiation: key effects on antigen presentation. J. Invest. Dermatol. (1995) 105(1 Suppl.):30S–36S.
   Google Scholar
• KRIPICE ML: Ultraviolet radiation and immunology: something new under the sun - presidential address. Cancer Res. (1994) 54:6102–6105.
   PubMed Web of Science ®Google Scholar
• TZIANABOS AO, ONDERDONK AB, ROSNER B et al.: Struc-tural features of polysaccharides that induce intra-ab-dominal abscesses. Science (1993) 262:416–419.
   PubMed Web of Science ®Google Scholar
• TZIANABOS AO, ONDERDONK AB, SMITH et al.: Struc-ture-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect. Immun. (1994) 62:3590–3593.
   PubMed Web of Science ®Google Scholar
• EDMONDS SE, ELLIS G, GAFFNEY K et al.: Hypoxia andthe rheumatoid joint: immunological and therapeutic implications. Scand. j Rheumatol. Suppl. (1995) 101163–168.
   Google Scholar
• SHERMAN DI, WILLIAMS R: Liver damage: mechanismsand management. Br. Med. Bull. (1994) 50:124–138.
   PubMed Web of Science ®Google Scholar
• LOVE RA, RADER JI, CROFFORD LJ et al.: Pathological andImmunological effects of ingesting L-tryptophan and 1-1'-ethylidenebis (L-tryptophan) in Lewis rats. J. Clin. Invest. (1993) 91:804–811.
   PubMed Web of Science ®Google Scholar
• DRISKELL WJ, ASHLEY DL, GRAINGER J et al.: Identifica-tion of decomposition products of 1,1'-ethylidenebis (L-tryptophan), a compound associate with eosino-philia-myalgia syndrome. Bull. Environ. Con tam. Taxkol. (1992) 48:679–687.
   PubMed Web of Science ®Google Scholar
• POL S: Immunotherapy of chronic hepatitis B by anti-HBV vaccine. Biomed. Pharmacother. (1995) 49:105–109.
   PubMed Web of Science ®Google Scholar
• REDFIELD RR, BIRX DL: HIV-specific vaccine therapy:concepts, status, and future directions. AIDS Res. Human Retroviruses (1992) 8:1051–1058.
   PubMed Web of Science ®Google Scholar
• BARTH A, HOON DS, FOSHAG LI et al.. Polyvalent mela-noma cell vaccine induces delayed-type hypersensitiv-ity and in vitro cellular immune response. Cancer Res. (1994) 54:3342-3345. John Rhodes, Immunology Unit, Research Division, Glaxo Wellcome Research & Development, Beckenham, Kent, UK.
   Google Scholar